China SXT Pharmaceuticals, Inc. Accounts Receivable, before Allowance for Credit Loss
Financial Statements › Balance Sheet › Assets › Accounts Receivable, after Allowance for Credit Loss
us-gaap:AccountsReceivableGross · last filed 2026-07-01
- 2026-03-31: Accounts Receivable, before Allowance for Credit Loss $2.87M.
- 2025-09-30: Accounts Receivable, before Allowance for Credit Loss $3.35M.
- 2025-03-31: Accounts Receivable, before Allowance for Credit Loss $3.38M.
- 2024-09-30: Accounts Receivable, before Allowance for Credit Loss $3.45M.
| Period end | Accounts Receivable, before Allowance for Credit Loss |
|---|---|
| 2026-03-31 | $2.87M 20-F · filed 2026-07-01 |
| 2025-09-30 | $3.35M 6-K · filed 2025-12-31 |
| 2025-03-31 | $3.38M 20-F · filed 2026-07-01 |
| 2024-09-30 | $3.45M 6-K · filed 2025-03-28 |
| 2024-03-31 | $3.05M 20-F · filed 2025-07-31 |
| 2023-09-30 | $2.77M 6-K · filed 2024-04-05 |
| 2023-03-31 | $2.87M 20-F · filed 2024-08-13 |
| 2022-09-30 | $2.83M 6-K · filed 2023-02-24 |
| 2022-03-31 | $4.10M 20-F · filed 2023-07-31 |
| 2021-09-30 | $3.00M 6-K · filed 2022-01-14 |
| 2021-03-31 | $4.78M 20-F/A · filed 2023-05-19 |
| 2020-09-30 | $5.69M 6-K · filed 2021-01-28 |
| 2020-03-31 | $3.92M 20-F · filed 2021-08-13 |
| 2019-09-30 | $4.63M 6-K/A · filed 2020-05-22 |
| 2019-03-31 | $4.25M 20-F · filed 2020-07-31 |